Navigation Links
Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/21/2007

rrently available drugs.

"Assessment of In Vitro Activity of Cethromycin Against Strains of Haemophilus Influenzae"

Cethromycin demonstrated potent in vitro activity against all Haemophius influenzae isolates studied regardless of beta-lactamase status. Based on the MIC data, cethromycin potency was comparable to telithromycin and azithromycin, and was superior to clarithromycin. These findings demonstrate that cethromycin has the potential to be a potent therapeutic option for the treatment of CAP caused by Haemophilus influenzae.

The following poster presentations demonstrated the potency of cethromycin as a potential treatment against bioterrorism pathogens:

"Efficacy of Cethromycin Against a Lethal Inhalation Anthrax Challenge in Rhesus Macaques"

All antibiotic treated animals maintained normal hematologic parameters and remained abacteremic throughout the treatment period. All cethromycin- treated animals survived, with only 1/10 demonstrating abnormal hematologic parameters following antibiotic cessation. One ciprofloxacin-treated animal demonstrated clinical signs of infection, bacteremia, alterations in hematologic and coagulation parameters, and died nine days after cessation of antibiotic treatments. All 10 control monkeys demonstrated a combination of clinical signs of anthrax, bacteremia, and/or alterations in hematologic and coagulation parameters post-challenge with five of ten succumbing to the infection. This study demonstrated that a thirty day course of oral cethromycin was 100% protective against a lethal dose of inhaled Bacillus anthracis Ames strain spores.

"Antimicrobial Activity of Cethromycin, a Novel Ketolide, Tested Against a Diverse Collection of Francisella Tularensis Strains"

Cethromycin was efficacious against 30 Francisella tularensis strains. Cethromycin had significant in vitro activity against Francisella tularensis. Cethromycin preferentially accumulates in the alveolar cells of the lungs,
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
7. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
8. Managing Preanalytical Processes for Patient Safety
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... and MARSEILLE, France , July 24, ... global license from University of Tokyo enables development of ... gene panels, for blood cancers  Mutations of ... favorable prognosis for patients with bone marrow disorders known ... developing companion diagnostics to guide treatment with new anti-cancer ...
(Date:7/24/2014)... 2014  IRIDEX Corporation (NASDAQ: IRIX ) ... 2014 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, July 31, 2014 to ... developments. Interested parties may access the live ...
(Date:7/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... announced its financial results for the second quarter ended June ... , Total revenues of $6.5 million in the second quarter ... in 2013 , Total revenues of $13.3 million for ... 78% over the same period in 2013 , Total ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... Sept. 12, 2011 The National Association of ... that facilitates cooperation between law enforcement, healthcare professionals, ... prevention and investigation of drug diversion – today ... survey by the Substance Abuse and Mental Health ...
... HAYWARD, Calif., Sept. 12, 2011 Intarcia Therapeutics, ... abstracts on ITCA 650 (DUROS® subcutaneous continuous delivery ... diabetes at the 47th Annual Meeting of the ... Lisbon, Portugal.  All three presentations are scheduled for ...
Cached Medicine Technology:Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 2Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 3Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 4
(Date:7/25/2014)... Ireland (PRWEB) July 26, 2014 ... quality legal help to people who have suffered ... the launch of both their new company, and ... article on the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims ... law. The focus of the company is always ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 In recent ... about, and eager to reverse the symptoms associated with age-related ... the media at large, a new case study ... real benefits of testosterone therapy using bioidentical hormones. , ... 38-year-old father from Seattle who found himself beginning to feel ...
(Date:7/25/2014)... 2014 A federal judge has denied ... DePuy Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ) selected ... to go before a jury on September 1, 2014, ... July 18th, U.S. District Judge Ed Kinkeade of the ... claims may proceed to trial against Johnson & Johnson, ...
(Date:7/25/2014)... York, NY (PRWEB) July 25, 2014 ... ticket prices across the board for the Guinness International ... FC and Olympiacos FC at Soldier Field on ... also offering their customer appreciation promo/coupon/offer code SOCCER-2014 for ... an amazing year for diehard soccer fans in North ...
(Date:7/25/2014)... of America (GSA) the nation,s largest ... has chosen Heather M. Young, PhD, RN, ... the 2014 recipient of the Doris Schwartz Gerontological ... by GSA,s Health Sciences Section, is given to ... outstanding and sustained contribution to gerontological nursing research. ...
Breaking Medicine News(10 mins):Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay ... early stage ,breast cancer using Herceptin and chemotherapy, while ... drug known as an anthracycline, improves survival while posing ... tested three different regimens, one of which did not ...
... CHAPEL HILL, N.C. -- Cam Patterson, MD, MBA, division ... at Chapel Hill School of Medicine has been named ... Association Judah Folkman Award in Vascular Biology. The ... at mid-career (within fifteen years of their first faculty ...
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay ... can safely undergo MRIs to screen for cancer and ... a new study finds. Those procedures include only ... or later or defibrillators manufactured in 2000 or later, ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... mice whose symptoms closely mimic autism in humans. ... the mice in this study come closer to mirroring ... in humans, said senior study author Matthew Anderson, an ...
... WEDNESDAY, Oct. 5 (HealthDay News) -- A new oral drug ... rates and disability progression, according to the results of a ... one of the few oral drugs that treat this type ... for many MS patients, researchers said. "Basically, these ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Oct. 5 ... listeria first linked to tainted cantaloupes has risen to 18, ... 20 states, the U.S. Centers for Disease Control and Prevention ... the cantaloupes in question were recalled Sept. 14, more cases ...
Cached Medicine News:Health News:Drug Combo Might Fight Aggressive Breast Cancer More Safely 2Health News:Drug Combo Might Fight Aggressive Breast Cancer More Safely 3Health News:MRI Safe With More Recent Defibrillators, Pacemakers: Study 2Health News:MRI Safe With More Recent Defibrillators, Pacemakers: Study 3Health News:Scientists Engineer Mice That Have Autism 2Health News:Scientists Engineer Mice That Have Autism 3Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 2Health News:18 Deaths From Cantaloupe-Linked Listeria Outbreak: CDC 3
Inquire...
... work area that will help protect your ... irradiate the work area prior to use, ... be amplified. Containment features reduce the chance ... acrylic windows for a clear view, an ...
... x 24in(h). Designed to protect against ... The PCR Workstation irradiates the workspace prior ... airborne contamination by limiting exposure of experimental ... two fluorescent lights, one UV light, 12 ...
... Electropolished stainless steel ... mounts dampen vibration to ... as isolating vibration-producing equipment ... low-profile design allows for ...
Medicine Products: